19:46:19 EDT Sun 19 May 2024
Enter Symbol
or Name
USA
CA



News for U:RPTX from 2023-05-18 to 2024-05-17 - 31 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-07 16:49U:RPTXSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-05-07 16:05U:RPTXNews ReleaseRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
2024-04-30 07:05U:RPTXNews ReleaseRepare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
2024-04-30 07:05U:RPTXNews ReleaseDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
2024-04-26 16:05U:RPTXNews ReleaseRepare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
2024-02-29 07:05U:RPTXNews ReleaseRepare Therapeutics to Participate in Two Upcoming Investor Conferences
2024-02-28 15:58U:RPTXSEDAR Annual Information FormSEDAR Annual Report
2024-02-28 15:01U:RPTXSEDAR Audited Annual Financial StatementsSEDAR MD & A
2024-02-28 07:05U:RPTXNews ReleaseRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-15 07:05U:RPTXNews ReleaseRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
2024-02-12 16:05U:RPTXNews ReleaseRepare Therapeutics to Regain Global Rights to Camonsertib
2024-01-25 07:00U:RPTXNews ReleaseRepare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
2024-01-08 07:00U:RPTXNews ReleaseRepare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
2024-01-04 16:05U:RPTXNews ReleaseRepare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
2023-12-29 16:05U:RPTXNews ReleaseRepare Therapeutics Insiders Establish Automatic Securities Disposition Plans
2023-11-15 07:00U:RPTXNews ReleaseRepare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol Ž ¸ Inhibitor
2023-11-09 11:30U:RPTXSEDAR Interim MD & ASEDAR Interim MD & A
2023-11-09 11:28U:RPTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 07:00U:RPTXNews ReleaseRepare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-11-07 07:00U:RPTXNews ReleaseRepare Therapeutics to Host Investor and Analyst Conference Call and Webcast
2023-10-13 09:40U:RPTXNews ReleaseRepare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
2023-10-03 07:00U:RPTXNews ReleaseRepare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-09-19 07:00U:RPTXNews ReleaseRepare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-09-06 07:00U:RPTXNews ReleaseRepare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-09 16:54U:RPTXSEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-09 16:05U:RPTXNews ReleaseRepare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-06-08 07:00U:RPTXNews ReleaseRepare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-07 16:05U:RPTXNews ReleaseRepare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
2023-06-06 07:00U:RPTXNews ReleaseRepare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
2023-06-02 07:00U:RPTXNews ReleaseRepare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
2023-05-22 07:00U:RPTXNews ReleaseRepare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)